Approval Date: November 14, 2007
Scoop: Mircera has a longer half-life than other commercially available erythropoiesis-stimulating agents (ESA). However, Roche lost a patent infringement case to Amgen, which markets the bestselling--and controversial--anti-anemia drugs Aranesp and Epogen. Though Mircera is available overseas, for the forseeable future it will not be marketed in the U.S.
Mircera gets FDA nod, but blocked by patent case. Report
Roche: Patent ruling won't stop Mircera. Report
Roche to Launch Mircera in UK and Germany. Report